Last reviewed · How we verify
Olimel N12
Olimel N12 is a Parenteral nutrition emulsion Small molecule drug developed by Erasmus Medical Center. It is currently FDA-approved for Parenteral nutrition support in patients unable to receive adequate oral or enteral nutrition, Post-operative nutritional support, Critical illness and intensive care nutrition.
Olimel N12 is a parenteral nutrition emulsion that provides balanced macronutrients (amino acids, glucose, and lipids) to support metabolic needs in patients unable to eat orally.
Olimel N12 is a parenteral nutrition emulsion that provides balanced macronutrients (amino acids, lipids, and carbohydrates) to support metabolic needs in patients unable to eat orally. Used for Total parenteral nutrition in patients unable to receive adequate oral or enteral nutrition, Post-operative nutritional support, Critical illness with gastrointestinal dysfunction.
At a glance
| Generic name | Olimel N12 |
|---|---|
| Sponsor | Erasmus Medical Center |
| Drug class | Parenteral nutrition emulsion |
| Modality | Small molecule |
| Therapeutic area | Nutrition support / Critical care |
| Phase | FDA-approved |
Mechanism of action
Olimel N12 is a complete all-in-one parenteral nutrition formulation combining amino acids for protein synthesis, glucose for energy, and lipid emulsion for essential fatty acids and additional calories. It is designed for intravenous administration to provide comprehensive nutritional support in clinical settings where oral or enteral feeding is not feasible or insufficient.
Approved indications
- Parenteral nutrition support in patients unable to receive adequate oral or enteral nutrition
- Post-operative nutritional support
- Critical illness and intensive care nutrition
Common side effects
- Hyperglycemia
- Hypertriglyceridemia
- Phlebitis at infusion site
- Electrolyte imbalances
- Hepatic dysfunction
Key clinical trials
- The Effect of Intradialytic Parenteral Nutrition on Nutritional Status and Quality of Life in Hemodialysis Patients (PHASE4)
- Long-term Muscle Synthetic Effects of Intradialytic Parenteral Nutrition in Chronic Hemodialysis Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olimel N12 CI brief — competitive landscape report
- Olimel N12 updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI
Frequently asked questions about Olimel N12
What is Olimel N12?
How does Olimel N12 work?
What is Olimel N12 used for?
Who makes Olimel N12?
What drug class is Olimel N12 in?
What development phase is Olimel N12 in?
What are the side effects of Olimel N12?
Related
- Drug class: All Parenteral nutrition emulsion drugs
- Manufacturer: Erasmus Medical Center — full pipeline
- Therapeutic area: All drugs in Nutrition support / Critical care
- Indication: Drugs for Parenteral nutrition support in patients unable to receive adequate oral or enteral nutrition
- Indication: Drugs for Post-operative nutritional support
- Indication: Drugs for Critical illness and intensive care nutrition
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing